Eradication Therapy for Helicobacter pylori with Diagnostic Test for Clarithromycin Resistance
The Korean Journal of Helicobacter and Upper Gastrointestinal Research
; : 225-230, 2019.
Article
en Ko
| WPRIM
| ID: wpr-786626
Biblioteca responsable:
WPRO
ABSTRACT
Addressing the increasing antibiotic resistance, including clarithromycin resistance, which affects Helicobacter pylori (H. pylori) eradication therapy, is a challenge for clinicians. Antibiotic resistance is the main reason for H. pylori eradication failure and the resistance rate for clarithromycin may drastically increase, up to 38.5%, due to 23S ribosomal RNA point mutations. Therefore, the standard triple regimen is no longer suitable as the first-line treatment in most regions. However, there is a growing interest in personalized care for patients. Increased eradication rates of tailored therapy based on antibiotic susceptibility have been reported using nucleic acid-based techniques for clarithromycin resistance with a focus on the first-line eradication therapy of H. pylori infection. Herein, we discuss the eradication therapy for H. pylori, with a diagnostic test and appropriate treatment for clarithromycin resistance.
Palabras clave
Texto completo:
1
Índice:
WPRIM
Asunto principal:
Resistencia a Medicamentos
/
Farmacorresistencia Microbiana
/
ARN Ribosómico 23S
/
Helicobacter pylori
/
Helicobacter
/
Mutación Puntual
/
Claritromicina
/
Pruebas Diagnósticas de Rutina
Tipo de estudio:
Diagnostic_studies
Límite:
Humans
Idioma:
Ko
Revista:
The Korean Journal of Helicobacter and Upper Gastrointestinal Research
Año:
2019
Tipo del documento:
Article